Literature DB >> 21423023

Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs.

Sarala Nicholas1, Kalpana Sabapathy, Cecilia Ferreyra, Francis Varaine, Mar Pujades-Rodríguez.   

Abstract

SETTING: Eight HIV programs in sub-Saharan Africa.
OBJECTIVE: To describe the incidence of pulmonary and extrapulmonary tuberculosis before and after the start of combined antiretroviral therapy (ART) and investigate associated risk factors.
DESIGN: Multicohort study. Adults enrolled between January 2006 and September 2008.
RESULTS: A total of 30,134 patients contributed 25,916 person-years of follow-up. The incidence of tuberculosis was 10.5 per 100 person-years during the pre-ART and 5.4 during the ART period. For all types of tuberculosis, incidence was similar in the pre-ART period and initial 3 months of ART but declined over time receiving ART (from 13 per 100 person-years in the first 3 months to 1.5 per 100 person-years after 12 months of therapy). Throughout follow-up, rates of pulmonary tuberculosis remained 2-fold to 3-fold higher than extrapulmonary tuberculosis rates. Smear-negative pulmonary tuberculosis was higher than smear-positive incidence and varied greatly across sites during the pre-ART period. Incidence was lower in rural sites, women, patients without prior history of tuberculosis, body mass index ≥18.5 kg/m², and ≥200 nadir CD4 cells per microliter. Recurrence rate was 1.7 per 100 person-years (95% confidence interval: 1.0 to 2.8).
CONCLUSIONS: Our findings show the high burden that tuberculosis represents for HIV programs and highlight the importance of earlier ART start and the need to implement intensified tuberculosis finding, isoniazide prophylaxis, and infection control.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21423023     DOI: 10.1097/QAI.0b013e318218a713

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  23 in total

1.  Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.

Authors:  Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Barudi Mosimaneotsile; Oaitse I Motsamai; Nong Shang; Charles E Rose; James Shepherd
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

2.  Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study.

Authors:  Mark W Tenforde; Ashish Yadav; David W Dowdy; Nikhil Gupte; Rupak Shivakoti; Wei-Teng Yang; Noluthando Mwelase; Cecilia Kanyama; Sandy Pillay; Wadzanai Samaneka; Breno Santos; Selvamuthu Poongulali; Srikanth Tripathy; Cynthia Riviere; Sima Berendes; Javier R Lama; Sandra W Cardoso; Patcharaphan Sugandhavesa; Parul Christian; Richard D Semba; Thomas B Campbell; Amita Gupta
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

Review 3.  Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.

Authors:  Stephen D Lawn; Anthony D Harries; Graeme Meintjes; Haileyesus Getahun; Diane V Havlir; Robin Wood
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

Review 4.  A systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in Africa.

Authors:  Yoshan Moodley; Kumeren Govender
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

Review 5.  Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.

Authors:  E L Corbett; P MacPherson
Journal:  Int J Tuberc Lung Dis       Date:  2013-09       Impact factor: 2.373

6.  Tuberculosis among HIV-infected population: incidence and risk factors in rural Tanzania.

Authors:  K Said; S Verver; A Kalingonji; F Lwilla; A Mkopi; S Charalambous; K Reither
Journal:  Afr Health Sci       Date:  2017-03       Impact factor: 0.927

7.  Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.

Authors:  Ankur Gupta; Robin Wood; Richard Kaplan; Linda-Gail Bekker; Stephen D Lawn
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

8.  The impact of implementing a Xpert MTB/RIF algorithm on drug-sensitive pulmonary tuberculosis: a retrospective analysis.

Authors:  K Rees; N Muditambi; M Maswanganyi; J Railton; J A McIntyre; H E Struthers; P B Fourie; R P H Peters
Journal:  Epidemiol Infect       Date:  2017-12-06       Impact factor: 4.434

9.  C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.

Authors:  Mark W Tenforde; Nikhil Gupte; David W Dowdy; David M Asmuth; Ashwin Balagopal; Richard B Pollard; Patcharaphan Sugandhavesa; Javier R Lama; Sandy Pillay; Sandra W Cardoso; Jyoti Pawar; Breno Santos; Cynthia Riviere; Noluthando Mwelase; Cecilia Kanyama; Johnstone Kumwenda; James G Hakim; Nagalingeswaran Kumarasamy; Robert Bollinger; Richard D Semba; Thomas B Campbell; Amita Gupta
Journal:  PLoS One       Date:  2015-02-26       Impact factor: 3.240

10.  Effect of Antiretroviral Therapy on HIV-mediated Impairment of the Neutrophil Antimycobacterial Response.

Authors:  David M Lowe; Nonzwakazi Bangani; Rene Goliath; Beate Kampmann; Katalin A Wilkinson; Robert J Wilkinson; Adrian R Martineau
Journal:  Ann Am Thorac Soc       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.